Safety, Efficiency and Treatment Satisfaction in Children with Primary Immunodeficiency Receiving Subcutaneous Immunoglobulin Treatment
نویسندگان
چکیده
منابع مشابه
Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
Antibody deficiency is the most frequently encountered primary immunodeficiency disease (PIDD) and patients who lack the ability to make functional immunoglobulin require life-long replacement therapy to prevent serious bacterial infections. Human serum immunoglobulin manufactured from pools of donated plasma can be administered intramuscularly, intravenously or subcutaneously. With the advent ...
متن کاملHyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
Immunoglobulin (Ig)-replacement therapy represents the mainstay of treatment for patients with primary antibody deficiency and is administered either intravenously (IVIg) or subcutaneously (SCIg). While hyaluronidase has been used in clinical practice for over 50 years, the development of a high-purity recombinant form of this enzyme (recombinant human hyaluronidase PH20) has recently enabled t...
متن کاملcomparison of zoe and vitapex for canal treatment of necrotic primary teeth
چکیده ندارد.
15 صفحه اولHuman normal immunoglobulin in the treatment of primary immunodeficiency diseases
The primary antibody deficiency syndromes are a rare group of disorders that can present at any age, and for which delay in diagnosis remains common. Replacement therapy with immunoglobulin in primary antibody deficiencies increases life expectancy and reduces the frequency and severity of infection. Higher doses of immunoglobulin are associated with reduced frequency of infection. Late diagnos...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Northern Clinics of Istanbul
سال: 2021
ISSN: 2148-4902
DOI: 10.14744/nci.2020.16870